Drug
Tgr 1202 Brentuximab Vedotin
Tgr 1202 Brentuximab Vedotin: highest development phase Phase 1, developed by TG Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- TG Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| TGR-1202 + brentuximab vedotin NCT02164006 | Phase 1 | Hodgkin's Lymphoma |
Latest
No recent events.
Follow Tgr 1202 Brentuximab Vedotin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.